Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03023397 · ClinicalTrials.gov registry record · Phase 1

Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.

A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.

Terminated
Registry status
Phase 1
Development phase
12
Enrollment target

NCT03023397 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03023397, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.

TERMINATED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of Dermatophagoides farinae (Der f), or house dust mite, extract in e-cigarette users, cigarette smokers, and non-smokers.

Interventions

  • BIOLOGICAL Der f

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-03-27
Est. Completion 2018-04-23
Phase Phase 1

What the Registry Record Tells You About NCT03023397

The ClinicalTrials.gov registry entry for NCT03023397 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Der f is the first listed.

NCT03023397 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03023397 about?

NCT03023397 is a clinical study titled "Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.". The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of Dermatophagoides farinae (Der f), or house dust mite, extract in e-cigarette users, cigarette smokers, and non-smokers.

What is the current status of trial NCT03023397?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-03-27. Estimated completion is 2018-04-23.

What interventions are being tested in trial NCT03023397?

The interventions under investigation include: Der f (BIOLOGICAL).

Who is sponsoring clinical trial NCT03023397?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.